← Leaderboards
Kamal V. Kannan
Metaclipse Therapeutics Corporation
$930,008
Attributed
$1,860,016
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$1,860,016 · 1
By mechanism
R44$1,860,016 · 1
Top collaborators
- Christopher D Pack3 shared
Most similar at Metaclipse Therapeutics Corporation
Same institution · by research overlap
- Christopher Pack$4,733,437
Others in their field
Other Emerging Leaders on “Immune Checkpoint Blockade”
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$17,572,948
- Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
- J. Silvio Gutkind · University Of California, San Diego$7,272,837
- Eti Yoles · Immunobrain Checkpoint Inc.$5,749,685
- Vinod P Balachandran · Sloan-Kettering Inst Can Research$5,168,008
- Sana D Karam · University Of Colorado Denver$4,851,223
Research focus
Immune Checkpoint BlockadeIncidenceDoseGrantImmunizationImmunotherapyCritical PathwaysCyclic GmpErbb2 GeneGlycosylationAutologousAntigen TargetingAwardCancer ImmunotherapyCost EffectiveCancer SubtypesCancer TypeBenchmarkingEffective TherapyEpitopesEstrogen ReceptorsGlycolipidsClinicMalignant Breast Neoplasm
Grant awards (3)
IND enabling studies for a personalized immunotherapy for triple negative breast cancer$80,133
R44 · FY2019 · CA · contact PI
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$1,079,344
R44 · FY2018 · CA · contact PI
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$700,539
R44 · FY2017 · CA · contact PI